Advertisement

Journal of Autism and Developmental Disorders

, Volume 30, Issue 5, pp 451–459 | Cite as

Pharmacotherapy for Hyperactivity in Children with Autism and Other Pervasive Developmental Disorders

  • Michael G. Aman
  • Kristen S. Langworthy
Article

Abstract

We reviewed pharmacological treatments used in children with autism and PDD-NOS who present with hyperactive symptoms. Some 41 studies were identified from the following drug categories: antipsychotics (n = 13), serotonin reuptake inhibitors (n = 3), antianxiety drugs (n = 4), psychostimulants (n = 10), alpha adrenergic agonists (n = 2), opiate blockers (n = 7), and other drugs (n = 2). Empirical evidence for significant reductions in hyperactive symptoms was strongest for the antipsychotics, psychostimulants, and naltrexone. Most studies have focused on the reduction of overactivity, and more emphasis needs to be placed on distractibility and attentional variables. A theoretical model was proposed in which participants' attentional performance may be used to predict clinical response to psychostimulants. More carefully controlled and comprehensive studies of hyperactivity are badly needed in these children.

Autism hyperactivity PDDNOS overactivity pharmacotherapy inattention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Aman, M. G. (1982). Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. Journal of Autism and Developmental Disorders, 12, 385–398.Google Scholar
  2. Aman, M. G. (1996). Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities, 8, 347–365.Google Scholar
  3. Aman, M. G., Van Bourgondien,, M. E., Wolford, P. C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672–1681.PubMedGoogle Scholar
  4. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.Google Scholar
  5. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195–1202.PubMedGoogle Scholar
  6. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Development Disorders, 19, 227–239.Google Scholar
  7. Barron, J. L., & Sandman, C. A. (1985). Paradoxical excitement to sedative-hypnotic drugs in mentally retarded clients. American Journal of Mental Deficiency, 90, 124–129.PubMedGoogle Scholar
  8. Birmaher, B., Quintana, H., & Greenhill, L. L. (1988). Methylphenidate treatment of hyperactive autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 248–251.PubMedGoogle Scholar
  9. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640–655.PubMedGoogle Scholar
  10. Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.PubMedGoogle Scholar
  11. Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koh, C. (1972). Response to tri-iodothyronine and dextroamphetamine: A study of preschool schizophrenic children. Journal of Autism and Childhood Schizophrenia, 2, 343–358.PubMedGoogle Scholar
  12. Campbell, M., Overall, J. E., Small, A. M., Sokol, M. S., Spencer, E. K., Adams, P., Foltz, R. L., Monti, K. M., Perry, R., Nobler, M., & Roberts, E. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 200–206.PubMedGoogle Scholar
  13. Campbell, M., Small, A. M., Collins, P. J., Friedman, E., David, R., & Genieser, N. (1976). Levodopa and levoamphetamine: A crossover study in young schizophrenic children. Current Therapeutic Research, 19, 70–86.PubMedGoogle Scholar
  14. Fatemi, S. H., Realmuto, G. M., Khan, L., & Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: A longitudinal open trial. Journal of Autism and Developmental Disorders, 28, 303–307.Google Scholar
  15. Fisman, S., & Steele, M. (1996). Use of risperidone in pervasive developmental disorders: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 177–190.PubMedGoogle Scholar
  16. Frankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1991). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77–82.Google Scholar
  17. Geller, B., Guttmacher, L. B., & Bleeg, M. (1981). Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. American Journal of Psychiatry, 138, 388–389.PubMedGoogle Scholar
  18. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363–366.PubMedGoogle Scholar
  19. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447.PubMedGoogle Scholar
  20. Handen, B. L., Johnson, C. R., & Lubetsky, M. (in press). Efficacy of methylphenidate among children with autism and symptoms of ADHD. Journal of Autism and Developmental Disorders. Google Scholar
  21. Horrigan, J. P., & Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders, 27, 313–323.PubMedGoogle Scholar
  22. Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322–327.PubMedGoogle Scholar
  23. Joshi, P. T., Capozzoli, J. A., & Coyle, J. T. (1988). Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder. American Journal of Psychiatry, 145, 335–338.PubMedGoogle Scholar
  24. King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A.W., MacMahon, W., Cantwell, E., Davanzo, P. A., Dourish, C., Dykens, E. M., Jaselskis, C. A. Leventhal, B. L., Lubetsky, M. J., Myers, S. M., Ozonoff, S., Shah, B. G., Leavitt, J., Shape, M., Steele, E. W., Williamson, K., & Cook, Jr., E. H. (1999, October). A double blind placebo controlled study of amantadine hydrochloride in treatment of children with autistic disorder. Poster presentation given at the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Chicago, IL.Google Scholar
  25. Kolmen, B. K., Feldman, H., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: A double bind placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 223–231.PubMedGoogle Scholar
  26. Kolmen, B. K., Feldman, H., Handen, B. L., & Janosky, J. E. (1997). Naltrexone in young autistic children: Replication study and learning measures. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1570–1578.PubMedGoogle Scholar
  27. Locascio, J. J., Malone, R. P., Small, A. M., Kafantaris, V., Ernst, M., Lynch, N. S., Overall, J. E., & Campbell, M. (1991). Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacology Bulletin, 27, 119–126.PubMedGoogle Scholar
  28. Lovaas, O. I., Koegel, R. L., & Schreibman, L. (1979). Stimulus overselectivity in autism: A review of research. Psychological Bulletin, 86, 1236–1254.PubMedGoogle Scholar
  29. Lyon, M., & Robbins, T. (1975). The action of central nervous system stimulant drugs: A general theory concerning amphetamine effects. In W. B. Essman & L. Valzelli (Eds.), Current developments in psychopharmacology (Vol. 2). New York: Spectrum.Google Scholar
  30. Malek-Ahmadi, P., & Simonds, J. F. (1998). Olanzapine for autistic disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 902.PubMedGoogle Scholar
  31. Marrosu, F., Marrosu, G., Rachel, M. G., & Biggio, G. (1987). Paradoxical reactions elicited by diazepam in children with classic autism. Functional Neurology, 3, 355–361.Google Scholar
  32. McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685–693.PubMedGoogle Scholar
  33. McCormick, L. H. (1997). Treatment with buspirone in a patient with autism. Archives of Family Medicine, 6, 368–370.PubMedGoogle Scholar
  34. Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. American Academy of Child and Adolescent Psychiatry, 37, 372–376.Google Scholar
  35. Overall, J. E., & Campbell, M. (1988). Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical Psychology, 44, 708–716.PubMedGoogle Scholar
  36. Perry, R., Pataki, C., Munoz-Silva, D. M., Armenteros, J., & Silva, R. R. (1997). Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology, 7, 167–179.PubMedGoogle Scholar
  37. Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19, 37–44.PubMedGoogle Scholar
  38. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283–294.PubMedGoogle Scholar
  39. Rapoport, J. L., Buchsbaum, M. S., Weingartner, H., Zahn, T. P., Ludlow, C., & Mikkelsen, E. J. (1980). Dextro-amphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933–943.PubMedGoogle Scholar
  40. Realmuto, G. M., August, G. J., & Garfinkel, B. D. (1989). Clinical effect of buspirone in autistic children. Journal of Clinical Psychopharmacology, 9, 122–125.PubMedGoogle Scholar
  41. Robbins, T. W., & Sahakian, B. J. (1979). “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology, 18, 931–950.PubMedGoogle Scholar
  42. Sandman, C. A., & Barron, J. L. (1992). Paradoxical response to sedative/ hypnotics in patients with self-injurious behavior and stereotypy. Journal of Developmental and Physical Disabilities, 4, 307–316.Google Scholar
  43. Schmidt, K. (1982). The effect of stimulant medication in childhood-onset pervasive developmental disorder: A case report. Journal of Developmental and Behavioral Pediatrics, 3, 244–246.PubMedGoogle Scholar
  44. Sporn, A., & Pinsker, H. (1981). Use of stimulant medication in treating pervasive developmental disorder. American Journal of Psychiatry, 138, 997.Google Scholar
  45. Strayhorn, J. M., Rapp, N., Donina, W., & Strain, P. S. (1988). Randomized trial of methylphenidate for autistic child. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 244–247.PubMedGoogle Scholar
  46. Vitriol, C., & Farber, B. (1981). Stimulant medication in certain childhood disorders. American Journal of Psychiatry, 138, 1517–1518.Google Scholar
  47. Volkmar, F., Hoder, E. L., & Cohen, D. J. (1985). Inappropriate uses of stimulant medications. Clinical Pediatrics, 24, 127–130.PubMedGoogle Scholar
  48. Ullman, D. G. (1974). Breadth of attention and retention in mentally retarded and intellectually average children. American Journal of Mental Deficiency, 78, 640–648.PubMedGoogle Scholar
  49. Uvebrant, P., & Bauziene, R. (1994). Intractable epilepsy in children. The efficacy of lamotrigine treatment, including nonseizure-related benefits. Neuropediatrics, 25, 284–289.PubMedGoogle Scholar
  50. Werry, J. S., & Aman, M. G. (1984). Methylphenidate in hyperactive and enuretic children. In B. Shopsin & L. Greenhill (Eds.), The psychobiology of childhood: Profile of current issues (pp. 183–195). Jamaica, NY: Spectrum.Google Scholar
  51. Werry, J. S., & Aman, M. G. (1999). Anxiolytics, sedatives, and miscellaneous drugs. In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp, 433–469). New York: Plenum Medical Book.Google Scholar
  52. Willemsen-Swinkles, S. H. N., Buitelaar, J. K., van Berckelaer-Onnes, I. A., & van Engeland, H. (1999). Brief report: Six months continuation treatment in naltrexone-responsive children with autism: An open-label case-control design. Journal of Autism and Developmental Disorders, 29, 167–169.PubMedGoogle Scholar
  53. Willemsen-Swinkles, S. H. N., Buitelaar, J. K., & van Engeland, H. (1996). The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study. Society of Biological Psychiatry, 39, 1023–1031.Google Scholar
  54. Willemsen-Swinkles, S. H. N., Buitelaar, J. K., Weijnen, F. G., & van Engeland, H. (1995). Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research, 58, 203–215.PubMedGoogle Scholar
  55. World Health Organization. (1993). The ICD-10 classification of mental and behavioural disorders. Geneva: Author.Google Scholar
  56. Zeaman, D., & House, B. J. (1963). The role of attention in retardate discrimination learning. In N. R. Ellis (Ed.), Handbook of mental deficiency. New York: McGraw-Hill.Google Scholar
  57. Zuddas, A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry, 153, 738.Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Michael G. Aman
    • 1
  • Kristen S. Langworthy
    • 1
  1. 1.The Nisonger Center for Mental Retardation and Developmental DisabilitiesOhio State UniversityColumbus

Personalised recommendations